SI1114644T1 - Composition comprising NPH insulin (neutral protamine hagedorn insulin) - Google Patents

Composition comprising NPH insulin (neutral protamine hagedorn insulin)

Info

Publication number
SI1114644T1
SI1114644T1 SI9730387T SI9730387T SI1114644T1 SI 1114644 T1 SI1114644 T1 SI 1114644T1 SI 9730387 T SI9730387 T SI 9730387T SI 9730387 T SI9730387 T SI 9730387T SI 1114644 T1 SI1114644 T1 SI 1114644T1
Authority
SI
Slovenia
Prior art keywords
insulin
composition
nph
neutral protamine
protamine hagedorn
Prior art date
Application number
SI9730387T
Other languages
English (en)
Slovenian (sl)
Inventor
Ross G. Clark
James Q. Oeswein
Douglas A. Yeung
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of SI1114644T1 publication Critical patent/SI1114644T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9730387T 1996-08-13 1997-07-31 Composition comprising NPH insulin (neutral protamine hagedorn insulin) SI1114644T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/696,314 US5783556A (en) 1996-08-13 1996-08-13 Formulated insulin-containing composition
EP01106315A EP1114644B1 (en) 1996-08-13 1997-07-31 Composition comprising NPH insulin (neutral protamine hagedorn insulin)

Publications (1)

Publication Number Publication Date
SI1114644T1 true SI1114644T1 (en) 2002-12-31

Family

ID=24796556

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730387T SI1114644T1 (en) 1996-08-13 1997-07-31 Composition comprising NPH insulin (neutral protamine hagedorn insulin)

Country Status (16)

Country Link
US (1) US5783556A (xx)
EP (2) EP1114644B1 (xx)
JP (1) JP4187075B2 (xx)
AR (1) AR009066A1 (xx)
AT (2) ATE205722T1 (xx)
AU (1) AU731745B2 (xx)
CA (1) CA2261799C (xx)
DE (2) DE69714796T2 (xx)
DK (2) DK0918536T3 (xx)
ES (2) ES2180523T3 (xx)
HK (1) HK1042229B (xx)
IL (1) IL128128A (xx)
PT (2) PT918536E (xx)
SI (1) SI1114644T1 (xx)
WO (1) WO1998006423A1 (xx)
ZA (1) ZA976598B (xx)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6391312B1 (en) * 1997-01-23 2002-05-21 Sumitomo Pharmaceuticals Co., Limited Remedies for diabetes
WO1998039967A1 (en) * 1997-03-12 1998-09-17 The General Hospital Corporation A method for treating or preventing alzheimer's disease
EP2823812A1 (en) * 1998-02-02 2015-01-14 Trustees Of Tufts College Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
JP2002510653A (ja) * 1998-04-03 2002-04-09 カイロン コーポレイション 緩衝剤としてコハク酸を含有する注射可能なｉｇｆ処方物
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
IL145597A0 (en) * 1999-04-08 2002-06-30 Genentech Inc Composition based on oppositely-charged polypeptides
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
FR2826278B1 (fr) * 2001-06-20 2005-03-25 Lipha Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
AU2002360453C1 (en) * 2001-11-26 2009-06-18 The Brigham And Women's Hospital, Inc. Methods for treating autoimmune disorders, and reagents related thereto
US7727964B2 (en) * 2001-11-26 2010-06-01 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP2460530A3 (en) 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
US20110097385A1 (en) * 2003-03-04 2011-04-28 Ttdc Bio L.P. Delivery System for Drug and Cell Therapy
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CA2558835C (en) * 2004-03-12 2011-06-28 Biodel, Inc. Rapid acting drug delivery compositions
US7310544B2 (en) 2004-07-13 2007-12-18 Dexcom, Inc. Methods and systems for inserting a transcutaneous analyte sensor
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
CN101180081B (zh) * 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 稳定的多肽制剂
JP2008542235A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US20090147006A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Method and system for event based data comparison
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010089706A1 (en) 2009-02-04 2010-08-12 Ecole Polytechnique Federale De Lausanne (Epfl) Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20200028501A (ko) 2009-06-12 2020-03-16 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2482724A2 (en) 2009-09-30 2012-08-08 Dexcom, Inc. Transcutaneous analyte sensor
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
ES2965209T3 (es) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
EP3831402A1 (de) 2009-11-13 2021-06-09 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
JP6312262B2 (ja) 2012-07-12 2018-04-18 マンカインド コーポレイション 乾燥粉末薬物送達システム
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
NZ707168A (en) * 2012-12-26 2016-09-30 Wockhardt Ltd Pharmaceutical composition of insulins
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
MX2016008978A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
DK3229828T5 (da) 2014-12-12 2024-10-14 Sanofi Aventis Deutschland Formulering med fast forhold mellem insulin glargin og lixisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2022086953A1 (en) * 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
DE102021122096A1 (de) * 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) * 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5091173A (en) * 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
JPH0818999B2 (ja) * 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
CA2109794A1 (en) * 1991-05-24 1992-11-26 Timothy J. Rink Amylin and possibly insulin containing composition for the treatment of anorexia and related states
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
JPH0543453A (ja) * 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
JP3747416B2 (ja) * 1991-11-25 2006-02-22 インスティテュート オブ モレキュラー バイオロジー インコーポレイテッド 哺乳類の神経の増殖を促進する薬物
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
DE69320919T2 (de) * 1992-06-24 1999-05-12 Hot Pepper Wax Inc., Greenville, Pa. Organische pestizide
ES2174852T3 (es) * 1992-08-26 2002-11-16 Celtrix Pharma Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
EP0642350A4 (en) * 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
JPH09500088A (ja) * 1993-01-29 1997-01-07 アムジェン ボールダー インコーポレイテッド 創傷治癒用組成物
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
DK1044015T3 (da) * 1998-01-09 2008-12-08 Amylin Pharmaceuticals Inc Formuleringer med amylinagonistpeptider og insulin
KR100617286B1 (ko) * 1998-10-16 2006-08-30 노보 노르디스크 에이/에스 폐 송달을 위한 안정한 농축 인슐린 조제물
IL145597A0 (en) * 1999-04-08 2002-06-30 Genentech Inc Composition based on oppositely-charged polypeptides
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes

Also Published As

Publication number Publication date
DE69706872D1 (de) 2001-10-25
EP0918536A1 (en) 1999-06-02
EP1114644B1 (en) 2002-08-14
CA2261799C (en) 2009-09-08
DE69714796D1 (de) 2002-09-19
US5783556A (en) 1998-07-21
IL128128A (en) 2007-06-17
WO1998006423A1 (en) 1998-02-19
ES2180523T3 (es) 2003-02-16
JP4187075B2 (ja) 2008-11-26
DE69714796T2 (de) 2003-04-03
EP1114644A1 (en) 2001-07-11
HK1042229A1 (en) 2002-08-09
HK1042229B (zh) 2003-08-15
AU3824397A (en) 1998-03-06
IL128128A0 (en) 1999-11-30
PT1114644E (pt) 2002-12-31
DK0918536T3 (da) 2001-12-03
AR009066A1 (es) 2000-03-08
DE69706872T2 (de) 2002-04-25
AU731745B2 (en) 2001-04-05
ES2162321T3 (es) 2001-12-16
PT918536E (pt) 2002-03-28
ATE205722T1 (de) 2001-10-15
JP2000516229A (ja) 2000-12-05
EP0918536B1 (en) 2001-09-19
DK1114644T3 (da) 2002-11-04
ATE222120T1 (de) 2002-08-15
CA2261799A1 (en) 1998-02-19
ZA976598B (en) 1999-02-17

Similar Documents

Publication Publication Date Title
HK1042229A1 (en) Composition comprising nph insulin (neutral protamine hagedorn insulin)
PL340255A1 (en) Non-dissolving insulin compositions
AU6208294A (en) Bleach catalyst composition
AU7506794A (en) Bleach catalyst composition
AU3308195A (en) Antihypertriglyceridemic composition
AU7506694A (en) Bleach catalyst composition
AU7606198A (en) Coloring composition
AU5335798A (en) Stomatic composition
PL310371A1 (en) Plasticiser composition
AU8747498A (en) Food-preservative composition
HU9602087D0 (en) Glass composition
AU7437094A (en) Disinfectant-detergent composition
AU8990298A (en) Improvements in or relating to contrast agents
AU8121998A (en) Composition
AU5844498A (en) Antifungal composition
AU6115694A (en) Bleaching composition
GB2285267B (en) Ceramic composition
AU8816198A (en) Improvements in or relating to contrast agents
AU672124B2 (en) Composition
AU1098499A (en) Emulsifier-lipid composition
AU1384799A (en) Novel igf-i composition and its use
IL139933A0 (en) A liquid composition containing recombinant interferon-beta
AU3530895A (en) Polyurethane composition
AU6128398A (en) New composition
AU2813195A (en) Composition